Tanvex BioPharma, Inc. (TPE: 6541)

Market Cap	11.24B
Revenue (ttm)	40.96M
Net Income (ttm)	-1.62B
Shares Out	164.07M
EPS (ttm)	-10.98
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	304,231
Average Volume	160,978
Open	65.10
Previous Close	65.10
Day's Range	65.10 - 68.50
52-Week Range	35.05 - 80.00
Beta	0.46
RSI	61.28
Earnings Date	Mar 7, 2025

About Tanvex BioPharma

Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company’s products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 139
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 6541

Financial Performance

In 2023, Tanvex BioPharma's revenue was 61.41 million, an increase of 174.11% compared to the previous year's 22.40 million. Losses were -2.14 billion, 30.2% more than in 2022.